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Summary
Purpose: To evaluate the long-term efficacy, tolerability, and safety of oxcarbazepine
(OXC) in children with epilepsy.
Methods: We enrolled 36 patients (median age 7.75) with new diagnosis of partial
epilepsy in an open prospective study. All type of epilepsy were included: 25 patients
were affected by idiopathic epilepsy, eight by symptomatic epilepsy and three by
cryptogenic epilepsy. Patients were then scheduled to come back for controls at 3
months (T1), 12 months (T2) and 24 months (T3) after the beginning of OXC-mono-
therapy (T0). At each control we evaluated patients through their seizure diary, a
questionnaire on side effects, their level of 10-monohydroxy (MHD) metabolite and
laboratory analysis.
Results: At T1, 21/36 patients (58.3%) were seizure-free, 3/36 patients (8.3%)
showed an improvement higher than 50%, 3/36 (8.3%) lower than 50%, while 2/36
worsened (5.6%). In 7/36 (19.5%) patients, no improvement was reported. At T2 13/18
patients (72.2%) were seizure-free, 1/18 showed a response to therapy higher than
50% while 2/18 worsened (11%). In two patients no improvement was reported. A
correspondence between MHD plasmatic levels and clinical response (r = 0.49;
p < 0.05) was only registered at T1.
An EEG normalization was observed in 25% of cases. Side effects were reported in
25% of cases, but symptoms progressively disappeared at follow-up.
Conclusions: We can therefore conclude that OXC can be considered, for its efficacy
and safety, as a first line drug in children with epilepsy.
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Oxcarbazepine (OXC) is a keto-analogue of carba-
mazepine (CBZ), with a similar spectrum of activity
and anticonvulsant efficacy, but its pharmacoki-
netic, safety and tolerability profiles seem to be
more favorable than its analogue.1—4
OXC is metabolized primarily through reductive
bio-transformation and conjugation (glucuronida-Table 1 Study design: timing of enrolment patients and d
T1 "mg/kg
January—March 2003 N 6
SF 3
R 0 3
NR 3
E 0
April—June 2003 N 5
SF 3
R 1
NR 1 1
E 0
July—September 2003 N 4
SF 2
R 0
NR 2
E 2
October—December 2003 N 3
SF 2
R 0
NR 1 1
E 0
January—March 2004 N 4
SF 1
R 0
NR 3 1
E 2
April—June 2004 N 7
SF 5
R 2
NR 0
E 0
July—September 2004 N 4
SF 3
R 0
NR 1 1
E 0
October—December 2004 N 3
SF 2
R 0
NR 1 1
E 0
N, total number cases investigated; SF, seizure-free; r, responder gr
months after the beginning of therapy; T3, evaluation at 12 months a
the beginning of therapy.tion) to the active 10-monohydroxy derivate
(MHD) that is the main active metabolite.5 More-
over, it has a low propensity to inhibit or induce
oxidative enzymes and has a small potential for
drug—drug interactions.
OXC is a second-generation antiepileptic drug
(AED), with proven efficacy as monotherapy6—8
and combination therapy9 for the treatment of
partial seizures (including subtypes of simple, com-iscontinuation/completion treatment
T2 "mg/kg T3 Seizure-free for 2 years
6 5
3 4 2
1 2 0
2 1
1
5 4
3 4 3
0
2 1
1
2
2
3
3
2
2
eater 50%; NR, non-responder; E, dropouts; T1, evaluation at 3
fter the beginning of therapy; T3, evaluation at 24 months after
294 E. Franzoni et al.plex and partial secondarily generalized seizures) in
adults6,10,11 and children with epilepsy.9,12
OXC-monotherapy could be initiated at 300 mg/
day and titrated at weekly intervals by 300 mg/
day.10
A previous treatment with carbamazepine can be
switched to OXC overnight13 or can gradually be
replaced by OXC,14 both in add-on and monother-
apy. On the contrary, a gradual switch over 2—3
weeks is more appropriate in patients receiving
AEDs other than CBZ.10
In general, side effects are similar to those of CBZ
(gait instability, dizziness, drowsiness, nausea and
vomiting, fatigue, headache, ataxia, sedation,
hyponatraemia, mild skin rashes, serious hypersen-
sitivity reactions, diplopia) although they tend to be
less severe and less frequent.11,15,16
This study is an open prospective analysis about
efficacy, tolerability and safety of OXC.Patients and methods
Thirty-six patients were enrolled between January
2003 and December 2004.
Inclusion criteria: age 2 years,
 diagnosis of symptomatic, idiopathic and crypto-
genic epilepsy according to the International Lea-
gue Against Epilepsy (ILAE),17,18 partial or complex or secondarily generalized
seizures, patients not previously treated with antiepileptic
drug, 2 seizures in the previous month,
 informed consent by parents and/or caregivers.
Exclusion criteria: poor compliance by parents/caregivers,
 myoclonic epilepsy and absence epilepsies,
 gFigure 1 Treatment efficacy in relation to aetiology.eneralized epilepsy.
Timing of enrollment is shown in Table 1.
Patients were only treated with OXC and did not
receive any other co-medication during the study.
At the following control, if seizures frequency
was still high, the dose was increased by 10 mg/kg.
Each patient was scheduled to attend periodic
clinical controls the first being 3 months (T1) after
the beginning of OXC-monotherapy (T0).
A second check (T2) was made 12 months after
since the introduction of OXC (T0); if laboratory
analysis, general and neurological examinations
were normal and seizure frequency had decreased,the following examinations were performed at 24
months (T3).
At each control (T1, T2, T3) the total number of
seizures occurred during follow-upwere analyzed by
using a seizure diary and side-effects with a ques-
tionnaire. In addition, EEG, MHD levels and labora-
tory analysis, in particular white cells count,
electrolytes balance, hepatic functional enzymes
and cholestasis indexes were evaluated.
Patients were considered responders when their
seizure rate decreased by more than 50% versus
baseline.
The last evaluation was performed in May 2005.
At present, 36 patients have been examined at
T1, 18 at T2 and 9 at T3.
Statistical analysis
The Statistical Package for Social Science 11.0.1
computer program (SPSS inc., Chicago, IL) was used.
For statistical analysis, data distribution was ana-
lyzed with skewness and kurtosis coefficients and
Kolmogorov—Smirnov test. Data are expressed as
median and inter-quartile range (IQR); IQR is the
distance between the 25th and the 75th percentile.
Statistical significance was assessed using Wilcox-
on’s matched-pairs signed-rank test and Sperman’s
rank correlation. All nominally significant results at
p < 0.05 (two-tailed) were indicated.
The median age of the patients evaluated at T0
was 7.75 (5.7—11.0).Results
Demographic analysis
We report the results on 36 patients affected by
epilepsy: 25/36 (69.5%) with idiopathic epilepsy
(rolandic epilepsy in 18 cases, occipital Panayoto-
poulos epilepsy in two cases and occipital benign
infantile epilepsy in five cases), 8/36 (22.2%) with
symptomatic epilepsy (Table 3), 3/36 (8.3%) with
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Figure 2 Response to therapy in patients with simple
partial seizure (SPS), complex partial seizure (CPS) and
secondary generalized seizure (PSSG).cryptogenic epilepsy (Fig. 1). The type of seizures
was simple partial (SPS) in 18/36 cases (50%), com-
plex partial (CPS) in 8/36 (22.2%), secondarily gen-
eralized (PSSG) in 10/36 (27.8%) (Fig. 2).
Dose
At T1, patients were taking a median OXC dose of
15.4 mg/kg (10.2—23.5). The median dose was
18.7 mg/kg (12.5—25.5) at T2 and 20.5 mg/kg
(16.8—26) at T3 (Table 2).
Plasma levels
At T1, patients reached a MHD-median of 12.8 mg/
ml (9.8—15.5). At T2, the MHD median value was
15.3 mg/ml (11.7—21.6) (Table 2). The results of the
analysis showed a statistically significant correlation
between MHD plasmatic levels and the dose
expressed in mg/kg (r = 0.62; p < 0.0001). At T1,
a correspondence between MHD plasmatic levels
and reduction of seizures (r = 0.49; p < 0.05) was
reported. At T2 and T3, we could not confirm this
statistic correlation because of a smaller number of
samples available.
Efficacy
At T1, 21/36 patients (58.3%) were seizure-free, 3/
36 patients (8.3%) showed a reduction of seizures
higher than 50%, 3/36 (8.3%) lower than 50%, while
2/36 worsened (5.6%). In 7/36 (19.5%) of patients,
no improvement was reported. In the non-responderTable 2 Age, dose (mg/day) and plasma levels (mg/ml) m
Age mg/day
T1 8.2 (5.7—12.1) 300 (300—450)
T2 10 (7.7—13.5) 600 (450—600)
T3 10.5 (8.6—14.2) 675 (600—900)group, rolandic epilepsy was diagnosed in seven
patients, symptomatic epilepsy in nine cases and
cryptogenic epilepsy in one case. In this group the
dose was increased at T1 but only two cases of
rolandic epilepsy, two cases of symptomatic epi-
lepsy and one case of cryptogenic epilepsy reached
T2 control.
At T2 total amount of responders increased to
77.7% (14/18), with seizure-free percentage of
72.2% (13/18).
One patient with occipital epilepsy experienced a
reduction in seizure rate major than 50%. Two
patients showed a clinical worsening (10%) and in
two patients no improvement was reported. In this
group two patients suffered from rolandic epilepsy
and two patients from symptomatic epilepsy.
We have observed one child affected by rolandic
epilepsy who showed a worsening at T1 and became
seizure-free at T2. On the contrary, one child
affected by symptomatic epilepsy with SPS resulted
seizure-free at T1, but worsened at T2.
Only nine patients reached T3 control (Table 1).
Given the small number of subjects, statistical ana-
lysis was not performed. The responder percentage
was 72% (18/25) in idiopathic epilepsy (Fig. 1).
Among these, rolandic epilepsy is diagnosed in 10
patients and occipital epilepsy in seven patients.
Therefore, 10/18 patients with rolandic epilepsy
and all patients with occipital epilepsy responded
to therapy.
Eight patients with rolandic epilepsy did not
respond to therapy.
Responders were 4/8 (50%) among patients
affected by symptomatic epilepsy and 2/3 (66.6%)
among patients affected by cryptogenic epilepsy
(Fig. 1). Diagnosis of symptomatic epilepsy are sum-
marized in Table 3.
9/18 (50%) patients with SPS, 7/8 (90%) patients
with CPS and 8/10 (80%) patients with PSSG
responded to therapy (Fig. 2).
EEG
A good improvement in patients with previous focal
abnormalities was reported at T1. A normalization
of EEG was observed in 25% of the cases. Abnorm-
alities remained unmodified in 75% of the cases. No
EEG focal abnormalities became generalized after
drug onset. When the abnormalities were multifocaledian at T1 and T2
mg/kg mg/ml
15.4 (10.2—23.5) 12.8 (9.8—15.5)
18.7 (12.5—25.5) 15.3 (11.7—21.6)
20.5 (16.8—26) 15.1 (10.9—21.7)
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Table 3 Diagnosis in patients with symptomatic epi-
lepsy
N = 8 Diagnosis
Responders
1 Brain abscess
1 Perinatal lesion
1 Heterotopia
1 Cerebral infantile paralysis
1 Temporal right neoplasia
Non-responders
1 Herpes encephalitis
1 Post-surgical lesion
1 Dandy—Walker Syndromeat diagnosis, no differences were reported at the
following EEG controls.
Side effects
At T1, side effects were reported in 25% of the cases
(Table 4) and in one case only OXC had to be inter-
rupted due to excessive sedation.
In the remaining cases, the symptoms progres-
sively disappeared at follow-up.
Laboratory tests
A median of leukocyte quantity resulted equal to
6.99 (5.6—7.9  103 ml1) at various controls.
No case of hyponatraemia was reported as Na+
levels remained between 137 and 143 meq/l atTable 4 Side effects at T1, T2 and T3 stages
Side effects Number of cases
T1
stage
T2
stage
T3
stage
Dizziness — — —
Gait instability — — —
Drowsiness — — —
Nausea and vomiting — — —
Fatigue 3 1 —
Headache 2 2 1
Ataxia — — —
Sedation 4 1 —
Hyponatremia — — —
Mild skin rashes 1 — —
Serious hypersensitivity
reaction
— — —
Diplopia — — —
Memory deficit — 1 —
Muscular Pain 1 — —
Hyperphagia 1 — —
Agitation 1 — —various controls, whereas K+ levels were between
4.1 and 5.1 meq/l.
No hepatic dysfunctions were reported.
Withdrawal
At present, five patients are withdrawing from OXC
because they have now been seizure-free for 2 years
(T3). Five patients had to stop the treatment for
inefficacy at T1 and one for side effects (sedation) at
T2. Among these, idiopathic epilepsy was diagnosed
in four patients and symptomatic epilepsy in two
patients. These six patients did not complete the
study. Currently, 69.4% (25/36) of patients is still
under OXC treatment, showing both good response
to therapy and excellent tolerability.Discussion
OXC is a new AED characterized by good efficacy and
high tolerability in children with epilepsy.
Previous studies showed that OXC-monotherapy
at daily doses of 15—20 mg/kg (approximately 900—
1200 mg in adults) achieves complete seizure con-
trol in about 60% of previously untreated adults,
adolescents, and children with partial epilepsy.19,20
As far as efficacy is concerned, we did not find any
significant differences as regards efficacy in patients
affected by simple (50%), complex partial (90%), or
secondarily generalized (80%) (Fig. 2).
Paradoxically, OXC can exacerbate abnormalities
in EEG and frequency seizure in generalized or focal
idiopathic epilepsy.21,22 We have reported three
cases of worsening in patients affected by focal
idiopathic epilepsy but without EEG-abnormalities
exacerbation. On the contrary, a normalization of
EEG was observed in 25% of the cases.
A placebo-controlled, dose ranging trial per-
formed by Barcs et al.23 showed that the efficacy
of OXC increases linearly in accordance with the
drug dose. By medians of a statistical analysis, we
also noticed an important correlation between
the response to therapy and the dose expressed
in mg/kg.
No clear-cut relationship between plasma drug
concentration and clinical response was identified,
and, at present, there are no clear indications for
the routine monitoring of OXC plasma levels as a
guide to dosage adjustment.5,16 However, in our
study we reported a correlation between MHD plas-
matic levels and clinical outcome at T1, not con-
firmed in T2 and T3 probably because of the small
number of cases evaluated. Further statistical ana-
lysis will be performed to evaluate this result in a
higher number of patients.
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cally significant correlation between MHD plasmatic
levels and the dose expressed in mg/kg. This con-
firms a first order linear relationship between the
two values, previously shown in drug pharmacoki-
netic studies.5,24,25
The incidence of hyponatraemia reported in a
clinical study26 is 2.5% and increasing with age,
whereas, in our experience, a reduction of natrae-
mia levels was not observed.
The Quality Standards and the Therapeutics and
Technology Assessment Subcommittees of the Amer-
ican Academy of Neurology reported a percentage
of discontinuation due to adverse events equal to
14%.27,28
In our study OXC tolerability is high: 75% of the
patients did not present any side effects. In the
remaining 25%, side effects were minor or moderate
and decreasing at various controls. Among these,
only hyperphagia has not been described in litera-
ture. Only one patient had to stop the treatment
due to excessive sedation.
Both patients affected by symptomatic and by
idiopathic epilepsy responded to OXC treatment.
Seventy-two percent were idiopathic and 50%
were symptomatic. Unfortunately, the number
of children affected by symptomatic or crypto-
genic epilepsy is not high enough to reach a con-
clusion. Anyway, in meta-analysis the response to
OXC-monotherapy in adults with refractory epi-
lepsy was similar (47%).27,28 OXC could be indi-
cated, in particular, for patients affected by
idiopathic epilepsy characterized by high seizure
frequency.
Idiopathic epilepsy is characterized by benign
outcome and prompt response to antiepileptic drug.
Rolandic epilepsy, in particular, would not be
treated if the patient presented few seizures and
a good compliance by parents or caregivers. Ambro-
setto et al.29,30 suggested that anticonvulsant treat-
ment could be delayed until the third seizure
occurrence. It is reasonable to withhold anticonvul-
sant if the child and family are comfortable with this
approach.31,32
Actually, in clinical practice, it is quite common
to treat rolandic epilepsy, due to high seizure fre-
quency (weekly or monthly) and parental anxiety.
The response is usually quite prompt and drug
doses are not high in order to control seizures.
However, in our study, to get an optimal clinical
response it was necessary to increase the OXC dose
even in patients with benign centro-temporal
spikes.
Among the group of idiopathic epilepsy, we have
enrolled seven patients with occipital epilepsy, who
all resulted responders to treatment with OXC.It becomes then primarily important to choose an
effective, but also very well tolerated drug. In our
experience, as in literature, OXC fulfils both these
criteria.Conclusion
OXC is effective and very well tolerated both in
symptomatic and idiopathic epilepsy. We can there-
fore conclude that OXC can be considered a first line
drug in children with epilepsy, particularly in the
idiopathic form.References
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